Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story.
This retrospective report describes our 20 months'experience using intravitreal injections of bevacizumab for the treatment of several retinal diseases. We describe our experience after 1765 intravitreal injections of bevacizumab in the treatment of different proliferative retinopathies - retinopathy of prematurity, choroidal neovascularization, diabetic retinopathy, among others. We believe that the findings reported in this study move us closer to a better treatment for different pathologies. However, further studies need to be performed in order to determine the safety and long-term efficacy of intravitreal bevacizumab either as first line therapy, after failure of conventional therapy, or in combination with conventional therapy.
Quiroz-Mercado
Hugo
H
Retina Service of Asociacion Para Evitar La Ceguera en México, Mexico City, Mexico. hugoquiroz@yahoo.com
Ustariz-González
Orlando
O
Martinez-Castellanos
Maria A
MA
Covarrubias
Paola
P
Dominguez
Francisca
F
Sanchez-Huerta
Valeria
V
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D003930:Diabetic Retinopathy / Q000188:drug therapy; D006801:Humans; D007231:Infant, Newborn; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy; D012164:Retinal Diseases / Q000188:drug therapy*; D012171:Retinal Vessels; D012178:Retinopathy of Prematurity / Q000188:drug therapy; D012189:Retrospective Studies; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab